Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: AMPS, Biolife Solutions, Centogene, Ers Genomics, Exact Sciences, Fasmac, Glyconics, Hancock Jaffee, Helius Medical Technologies, HP, Merit Medical Systems, Opgen, Opsens, Paragon Genomics, Periandx, Pillar Biosciences, Sengenics, Summa Equity, Surlogs, U-Diagnostics, Veeva, Veo Diagnostics, Vivalnk, Wheeler Labs.

Med-tech firms raising money in public or private financings, including: Alphatec Holdings, Avricore Health, Broncus Holding, Nanostring Technologies.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bayer, Biohaven, Direct, Enlivex, Harmony, Moderna, Orca, Redhill, Scynexis, Sorrento, Taysha Gene, Tevogen, Y-mabs.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Arvinas, Bioclonetics, Blue Oak, Boehringer, Denali, Dendreon, Emmaus, Enzolytics, Exscientia, Gilead, Immunomedics, Kadmon, Lactiga, Mediwound, Moberg, Novan, Oxford, Passage, Polyphor, Qihan, Redhill, Rezolute, Secarna, Vaxart, Xoma.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Amolyt, Anaptysbio, Auris, Azurrx, Basilea, Bone Therapeutics, Celldex, Cyclerion, Cytoagents, Evelo, Horizon, Ionis, Linnaeus, Mesoblast, Noxxon, Revance, Shasqi, TLC.

Biopharmas raising money in public or private financings, including: Advanced Nanotherapies, Aridis, Biocure, Codiak, Eton, Immunome, Morphosys, Nimbus, Noxxon, Ocular, Oncopeptides, Resverlogix, Springworks, Vistagen.

New hires and promotions in the biopharma industry, including: Ambys, Curelab, Dewpoint, Flagship Pioneering, Medeor, Meissa, Myovant, Precision, Rapt, Recce, Ring, Seed, Sofinnova, Trevi.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Aim Immunotech, Akari, Altimmune, Ampio, Anpac Bio-Medical Science, Antengene, ATCC, Auravax, Beigene, Betterlife, Bintai Kinden, Bioatla, Biogen, Biontech, Bostongene, Citius, Complix, Corneagen, Cstone, Curon, Denali, Eisai, Eli Lilly, GT, Hitgen, ILC, IMV, Innovent, Invetech, Johnson & Johnson, Kaleido, Kemwell, Kindred, Laboratoires Théa, Ligand, Mapi, Molecular Partners, Moleculin, NEC, Novellus, Nugenerex Immuno-Oncology, Oblique, Ocugen, Olix, Oncimmune, Orbis International, Oxford Biomedica, Pfizer, Renibus, Rentschler, Rhizen, Santen, Shenzhen Hepalink, Sorrento, Spartina, Sumitomo Chemical, Sumitomo Dainippon, Sunovion, Sunshine, Transgene, Treefrog, Urovant Sciences, Vaxart, Vir, Virtrial, Wuxi.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Opthea.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Arca Biopharma, Arch Biopartners, Ascentage, Astrazeneca, Biogen, Biontech, Celltrion, Cerecin, Eli Lilly, Foresee, Gannex, Gemvax, Huya Bioscience, Innovent Biologics, Oragenics, Pfizer, Pluristem, Regeneron, Revelation, Samsung Bioepis, Taiwan Liposome, Xortx.